Starting February 1st for new prescriptions, Excellus will require the use of the biosimilar Inflectra (infliximab-dyyb) over Remicade (infliximab).
We recommend FDA’s biosimilar provider education and patient education materials.
135 Corporate Woods, Suite 320
Rochester, New York 14623-1466
Phone: (585) 758-7823
Fax: (585) 424-1268
© Copyright - Accountable Health Partners - 2024
Website by: 
This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.
| ABI Value | Interpretation | Recommendation |
|---|---|---|
| Greater than 1.4 | Calcification/vessel hardening | Refer to vascular specialist |
| 1.0 - 1.4 | Normal | None |
| 0.9 - 1.0 | Acceptable | None |
| 0.8 - 0.9 | Some arterial disease | Treat risk factor |
| 0.5 - 0.8 | Moderate arterial disease | Refer to vascular specialist |
| Less than 0.5 | Severe arterial disease | Refer to vascular specialist |
